Pulsenmore
Builds prescription-connected home ultrasound systems for remote clinician review.
Something off on this page? Send us feedback.
Profile
Provides prescription smartphone-connected home ultrasound systems, combining devices, guided apps, cloud transfer, and clinician dashboards for remote review. Revenue has centered on Pulsenmore ES and Israeli healthcare organizations, while U.S. use remains tied to prescribed, physician-interpreted care.
Combines a handheld prenatal ultrasound cradle with a mobile app, cloud service, and clinician dashboard. Pulsenmore ES lets prescribed patients acquire limited images at home while clinicians interpret them remotely; its FDA-authorized U.S. use is confined to fetal-heart-rate assessment in singleton pregnancies and does not replace routine or emergency care.
Sells chiefly through Israeli HMOs and hospitals, then uses specialist practices and virtual-maternity partners to enter the United States; activity also reaches Australia, Europe, and other markets. Pulsenmore FC supports home fertility monitoring in early Israeli commercialization, while Pulsenmore MC remains in clinical-feasibility development for lung-fluid monitoring.
Relies on provider prescriptions, physician review, compatible smartphones, cloud connectivity, regulatory authorization, reimbursement pathways, and component suppliers across Israel and East Asia.
Company facts
Key statistics
Year to date −65.1% · Average volume (30d) 55.6K
Analysts
No analyst consensus on record.
Earnings
Not reported.
Financial highlights
| 10 quarters | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | |
|---|---|---|---|---|---|---|---|
| Revenue | $807.7K | $1.2M | $1.5M | $1.8M | $1.3M | $13.0M | |
| Gross profit | $331.4K | $400.4K | $520.1K | $676.3K | $486.8K | $11.2M | |
| Operating income | −$9.6M | −$8.8M | −$6.7M | −$7.4M | −$6.9M | −$2.0M | |
| Net income | −$7.5M | −$12.0M | −$5.3M | −$7.0M | −$7.7M | −$3.0M | |
| Diluted EPS | −$1.20 | −$1.92 | −$0.85 | −$1.11 | −$1.21 | −$0.47 | |
| Gross margin | 41.0% | 32.0% | 35.8% | 38.1% | 36.4% | 85.6% | |
| Operating margin | -1,194.1% | -707.0% | -460.9% | -417.3% | -515.7% | -15.6% |
Revenue by geography · FY25
Balance sheet, Dec 31, 2025Cash & short-term investments $23.2M · Total debt $524.9K · Total assets $34.2M · Shareholders' equity $27.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 6.50M · Float 3.86M · 59.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Elazar Sonnenschein | 1.87M | 28.79% | 13G | Apr 28, 2026 |
| Jonathan Adereth · director | 129.1K | 1.98% | Form 4 | Mar 18, 2026 |
| Meir Shmouely · officer: VP Software Development | 13.8K | 0.21% | Form 4 | Mar 18, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- GE HealthCare
Wireless handheld ultrasound and clinician workflow in obstetric care.
- Butterfly Network
Smartphone-connected ultrasound and cloud workflow in obstetric care.
- Philips (ADR)
App-based handheld ultrasound for OB/GYN and maternal-care access.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Pulsenmore | $2.58 | +0.39% | $16.7M | — | — | 1.2 | — |
| GE HealthCare | $71.73 | −0.01% | $32.40B | 20.8 | 13.8 | 1.6 | +5.8% |
| Butterfly Network | $8.47 | +0.45% | $2.24B | — | — | 20.0 | +39.5% |
| Philips (ADR) | $26.72 | +0.06% | $26.12B | 19.9 | 13.7 | 1.3 | −2.9% |
| Median | 20.3 | 13.7 | 1.6 | +5.8% |